Patents by Inventor Scott Rodig

Scott Rodig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of immune disorders using galectin-1
    Patent number: 9939428
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring immune disorders, e.g., Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: April 10, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., Consejo Nactional De Investigaciones Cientificias Y Tecnicas, Fundacion Sales
    Inventors: Margaret A. Shipp, Przemyslaw Juszczynski, Jing Ouyang, Jeffery Kutok, Scott Rodig, Gabriel Rabinovich
  • Compositions, kits, and methods for the modulation of immune responses using galectin-1
    Patent number: 9206427
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: December 8, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., CONICET, Fundacion Sales
    Inventors: Margaret A. Shipp, Przemyslaw Juszczynski, Jing Ouyang, Jeffery Kutok, Scott Rodig, Gabriel Rabinovich
  • Compositions, Kits, and Methods for the Modulation of Immune Responses Using Galectin-1
    Publication number: 20090191182
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma.
    Type: Application
    Filed: July 17, 2008
    Publication date: July 30, 2009
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Przemyslaw Juszczynski, Jing Quyang, Jeffrey Kutok, Scott Rodig, Gabriel Rabinovich
  • Compositions, Kits, and Methods for the Diagnosis, Prognosis, and Monitoring of Immune Disorders Using Galectin-1
    Publication number: 20090176223
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring immune disorders, e.g., Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL.
    Type: Application
    Filed: July 17, 2008
    Publication date: July 9, 2009
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Przemyslaw Juszczynski, Jing Ouyang, Jeffrey Kutok, Scott Rodig, Gabriel Rabinovich